Acute coronary syndromes (unstable angina/non ST-segment elevation myocardial infarction), including patients who are to be managed medically and those undergoing percutaneous coronary intervention.
Acute Coronary Syndrome - IV bolus 180 μg/kg as soon as possible following diagno- sis, followed by a continuous infusion of 2.0 μg/kg/min until hospital discharge or initiation of CABG surgery, up to 72 hours. If a patient is to undergo a percutaneous coronary intervention [PCI] while receiving eptifibatide, the infusion should be continued up to hospital discharge, or for up to 18-24 hours after the procedure, which- ever comes first, allowing for up to 96 hours of therapy. Patients with creatinine clearance less than 50 mL/min -IV 180 μg/kg as soon as possible following diagnosis, immediately followed by a continuous infusion of 1.0 μg/kg/min. Percutane- ous Coronary Intervention [PCI] - IV 180 μg/kgadministered immediately before the initia- tion of PCI followed by a continuous infusion of 2.0 μg/kg/min and a second 180 μg/kg bolus 10 minutes after the first bolus.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
Eptifibatide reversibly inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive ligands to GP IIb/IIIa.
A history of bleeding diathesis, or evidence of active abnormal bleeding within the previous 30 days; severe hypertension; major surgery within the preceding 6 weeks; history of stroke within 30 days or any history of hemorrhagic stroke; current or planned administration of another parenteral GP IIb/IIIa inhibitor; dependency on renal dialysis; known hypersensitivity to any component of the product.
Bleeding; intracranial hemorrhage and stroke; thrombocytopenia; allergic reactions;